Chordate Medical presents interim report for Q1 2023

Chordate Medical Holding (publ) publishes its interim report for Q1 2023 on Thursday, May 25th, 2023, 08:30 a.m. On Friday, May 26th, 10:00 a.m., the company invites you to a live-streamed teleconference with CEO Anders Weilandt.

After the conference, there will be a question-and-answer session. The presentation is held in Swedish. It is possible to follow the conference via computer or mobile devices.

Register for the web conference here: https://attendee.gotowebinar.com/register/6316614468544567648

The number of places is limited, so we recommend registering well in advance to secure a place.

A recording of the web conference will be available after the conference on the company’s website www.chordate.com and on the Västra Hamnen Corporate Finance YouTube channel.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked a neuromodulation and drug-free treatment technology for chronic migraine and chronic nasal congestion (rhinitis), Kinetic Oscillation Stimulation (K.O.S). The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and Saudi Arabia. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy